A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): A cluster-randomised controlled trial

The Lancet Neurology

Volumn 12, Issue 2, 2013, Pages 139-148

  Scott, Phillip A ^a,b   Meurer, William J ^a,b   Frederiksen, Shirley M ^a,b   Kalbfleisch, John D ^b   Xu, Zhenzhen ^b   Haan, Mary N ^b,c   Silbergleit, Robert ^a,b   Morgenstern, Lewis B ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG USE; EMERGENCY WARD; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HOSPITALS, COMMUNITY; HUMANS; MALE; MICHIGAN; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84872600360     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70311-3     Document Type: Article

References (33)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
2. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
4. Hills NK, Johnston SC Why are eligible thrombolysis candidates left untreated?. Am J Prev Med 2006, 31(suppl 2):S210-S216.
5. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP National US estimates of recombinant tissue plasminogen activator use. Stroke 2008, 39:924-928.
6. Boode B, Welzen V, Franke C, van Oostenbrugge R Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis 2007, 23:294-298.
7. Albright KC, Branas CC, Meyer BC, et al. ACCESS: acute cerebrovascular care in emergency stroke systems. Arch Neurol 2010, 67:1210-1218.
8. Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke 2009, 40:3580-3584.
9. Brown DL, Lisabeth LD, Garcia NM, Smith MA, Morgenstern LB Emergency department evaluation of ischemic stroke and TIA: the BASIC Project. Neurology 2004, 63:2250-2254.
10. Policy compendium 2012: Use of intravenous tPA for the management of acute stroke in the emergency department. 2002; page 110 American College of Emergency Physicians, (accessed Dec 9, 2012). http://www.acep.org/Physician-Resources/Policies/2012-Policy-Compendium/ .
11. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med 2005, 46:56-60.
12. Meurer WJ, Majersik JJ, Frederiksen SM, Kade AM, Sandretto AM, Scott PA Provider perceptions of barriers to the emergency use of tPA for acute ischemic stroke: a qualitative study. BMC Emerg Med 2011, 11:5.
13. Aaron S, Alexander M, Maya T, Mathew V, Goyal M Treatment of acute ischemic stroke: awareness among general practitioners. Neurol India 2010, 58:441-442.
14. Rudd M, Rodgers H, Curless R, et al. Remote specialist assessment for intravenous thrombolysis of acute ischaemic stroke by telephone. Emerg Med J 2012, 29:704-708.
15. Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy: the TLL Temple Foundation Stroke Project. Stroke 2002, 33:160-166.
16. Morgenstern LB, Bartholomew LK, Grotta JC, Staub L, King M, Chan W Sustained benefit of a community and professional intervention to increase acute stroke therapy. Arch Intern Med 2003, 163:2198-2202.
17. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 2005, 36:1597-1616.
18. Scott PA, Frederiksen SM, Kalbfleisch JD, et al. Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams. Acad Emerg Med 2010, 17:1062-1071.
19. Scott PA Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation. Emerg Med Clin North Am 2009, 27:115-136.
20. Adams H, Adams R, Del Zoppo G, Goldstein LB Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005, 36:916-923.
21. Piriyawat P, Smajsova M, Smith MA, et al. Comparison of active and passive surveillance for cerebrovascular disease: the Brain Attack Surveillance in Corpus Christi (BASIC) Project. Am J Epidemiol 2002, 156:1062-1069.
22. Greco PJ, Eisenberg JM Changing physicians' practices. N Engl J Med 1993, 329:1271-1273.
23. Prabhakaran S, McNulty M, O'Neill K, Ouyang B Intravenous thrombolysis for stroke increases over time at primary stroke centers. Stroke 2012, 43:875-877.
24. Adeoye O, Hornung R, Khatri P, Kleindorfer D Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States. Stroke 2011, 42:1952-1955.
25. Prabhakaran S, McNulty M, O'Neill K, Ouyang B Intravenous thrombolysis for stroke increases over time at primary stroke centers. Stroke 2012, 43:875-877.
26. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get with the guidelines-stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009, 119:107-115.
27. The ATLANTIS Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363:768-774. ECASS, and NINDS rt-PA Study Group Investigators.
28. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012, 379:2352-2363. The IST-3 collaborative group.
29. Dirks M, Niessen LW, van Wijngaarden JD, et al. Promoting thrombolysis in acute ischemic stroke. Stroke 2011, 42:1325-1330.
30. Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 2012, 11:397-404.
31. Graham GD Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003, 34:2847-2850.
32. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369:275-282.
33. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004, 35:e27-e29.